Navigation Links
Precision radiation therapy may improve survival rates of some lung cancer patients
Date:3/16/2010

DALLAS March 16, 2010 A radiation therapy that uses multiple radiation beams to target tumors precisely has been shown to eliminate the primary tumor and ultimately may improve survival rates for lung-cancer patients unable to undergo surgery, according to UT Southwestern Medical Center physicians who led a national clinical trial of the treatment.

In a study appearing in the March 17 issue of The Journal of the American Medical Association, primary lung cancer did not recur in nearly 98 percent of the 55 participants who received stereotactic body radiation therapy (SBRT). More than half of these patients 56 percent were alive three years after diagnosis, while less than 20 percent ultimately died of metastatic lung cancer.

Dr. Robert Timmerman, vice chairman of radiation oncology at UT Southwestern, is lead author of the study and the principal investigator of the Radiation Therapy Oncology Group (RTOG) 0236 trial the first North American multicenter study to test SBRT in this patient population.

SBRT is a noninvasive procedure that delivers radiation beams to a tumor in a concentrated, extremely precise manner. Each of these beams is relatively weak and causes very little damage when traveling through the patient's body. When all the beams converge at the tumor, however, their cumulative effect delivers an extremely potent high dose aimed at destroying the target cells with great precision.

In this study, the 55 patients diagnosed with early-stage non-small cell lung (NSCL) cancer were unable to have their tumors surgically removed because of unrelated medical conditions, which left many of the subjects quite frail. Instead of conventional radiation therapy, which is often offered to such patients and is administered in 20 to 30 outpatient treatments, the participants were treated with SBRT during three outpatient treatments.

"Despite the high potency of the treatment, fewer than 20 percent of these extremely frail patients experienced a serious health decline," said Dr. Timmerman, who is considered one of the top international experts on stereotactic radiotherapy. "We believe these findings justify SBRT as a standard of care treatment for lung cancer in patients with serious medical problems like emphysema, heart disease and strokes.

"Primary tumor control is an essential requirement for the cure for lung cancer," he said. "SBRT as delivered in this clinical trial provided more than double the rate of primary tumor control as conventional radiotherapy described in earlier reports."

Dr. Timmerman said the patient outcomes in this study were better than researchers had expected and are similar to the risks for healthier patients who undergo radical surgery the standard treatment for early-stage NSCL cancer for the past century.

"The findings support ongoing clinical research that is investigating the use of SBRT in healthier patients who currently undergo surgery for their early-stage NSCL," Dr. Timmerman said. "SBRT is fast, convenient and very effective."


'/>"/>

Contact: Connie Piloto
connie.piloto@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
Source:Eurekalert

Related medicine news :

1. Medicare Supplement Plan N Information and Rates Now Available Through Precision Senior Marketing
2. Precision Therapeutics President and CEO Sean McDonald Recipient of 2009 Pacesetters Award
3. National Minority Quality Forum Creates Advanced, Precision Tracking Tool to Address Prevalence of Peripheral Arterial Disease
4. Gerber Life Medicare Supplement Now Available Through Precision Senior Marketing
5. New Precision Radiation Treatment System Fights Cancer
6. Utilizing GPS-like Measurement Precision To More Accurately Determine Overall Performance
7. Reell Precision Manufacturing Creates a New Category of Torque Control Hinges, Check Out the Reell Torque Insert
8. Media Advisory: Medco CEO David B. Snow Jr. To Address American Enterprise Institute: Health IT: Empowering Precision Medicine
9. New laser for neurosurgery allows greater precision and efficiency for removal of complex tumors
10. Precision Optics Corporation to Effect Reverse Split and Ticker Symbol Change
11. Siemens Next-Generation of C-Arms Demonstrate Precision Imaging and Ease of Use
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... ... July 21, 2017 , ... Sharon Kleyne ... signature product of her research center at Bio-Logic Aqua Research® Water Life Science®, ... the greatest number of sufferers of blindness. “We think that Nature’s Tears® EyeMist® ...
(Date:7/21/2017)... TORONTO, ONTARIO, CANADA (PRWEB) , ... July 21, ... ... may give insight into why concussion rates are on the rise, say researchers ... Annual Meeting today in Toronto, Ontario, Canada. , “The combination of evaluating the ...
(Date:7/20/2017)... ... July 20, 2017 , ... ... enterprise-grade IT operations analytics and application performance monitoring (APM) solutions, has expanded ... healthcare services providers. , According to Peter Ohrenberger, sales director at Nastel, ...
(Date:7/20/2017)... ... July 20, 2017 , ... Team Type 1 Foundation, a ... for everyone affected by diabetes, is teaming up with a Microsoft Corp. employee-led hackathon ... off on July 24th. , “Team Type 1’s mission overlaps seamlessly with Microsoft’s ...
(Date:7/20/2017)... ... July 20, 2017 , ... Using CDRH’s Medical Device ... — 1:30 p.m. – 3:00 p.m. ET, http://www.fdanews.com/mdqualitydata          , Device makers ... It’s known as the “CY2016 Annual FDA Medical Device Quality System Data” report. ...
Breaking Medicine News(10 mins):
(Date:7/6/2017)... division of Diplomat Specialty Infusion Group, is celebrating a decade of empowering ... celebrate its anniversary, ThriveRx recently launched a redesigned website at thriverx.diplomat.is ... to create the best user experience for consumers and health care professionals. ... Diplomat Pharmacy ... "We,ve made several great strides throughout the past 10 years," ...
(Date:7/5/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ... a clinical-stage pharmaceutical company focused on the development of oral ... from the Israel Securities Authority to dual-list its common stock ... will commence trading on the TASE on July 12, 2017 ... of the Company, it is expected that Oramed will be ...
(Date:7/5/2017)... Wash. , July 5, 2017   BioLife ... leading developer, manufacturer and marketer of proprietary clinical grade ... cryopreservation freeze media ("BioLife"), today announced that it ... its debt holder and largest shareholder, to modify its ... Pursuant to the modification, WAVI agreed to exchange ...
Breaking Medicine Technology: